PureTech Health plc

NASDAQ:PRTC

Biotechnology

Healthcare
$17.38 +2.64%

+$0.45 today

Market cap
$423.09M
Beta
0.79
P/E (TTM)
-0.4
EPS (TTM)
-$45.37
52W Low $14.50High $19.92

Volume 0.01M

Average 0.01M

PRTC Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

PureTech Health plcNASDAQ: PRTC

Total Equity · Q4 FY2025 · quarter ended Dec 2025

Total equity falls 25.1% from a year ago

Total equity stood at $305.68M at the end of Q4 FY2025, down 25.1% from a year earlier. Over 3 fiscal years it compounded at -17.7% a year.

Context

  • Total equity amounted to 57.2% of total assets at the end of Q4 FY2025, down 10.5 pp from a year earlier.
  • Total equity increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -25.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
$305.68M— QoQ
Last fiscal yearDec 2025
$305.68M-25.1% YoY
Year agoDec 2024
$407.93M-25.1% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.1%——
1 year-25.1%——
3-year CAGR-17.7%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
305.68M USD
Year-over-year change
-25.1%
4-year CAGR
-14.9%

Total Equity vs competitors

How PRTC compares with its peers on the latest reported figures

  • PRTC's Dec 2025 total equity of $305.68M is the 3rd highest of the 11 companies compared; the peer median is $192.04M.
  • Its year-over-year change of -25.1% is the 7th highest of 11, against a peer median of -18.6%.
  • Total equity amounts to 57.2% of total assets for PRTC, versus a peer median of 82.0%.
PRTC Competitors Peer median
Total Equity for PRTC and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ALMSAlumis Inc. Common StockJun 2026$452.16M -6.8%—80.7%
SLDBSolid Biosciences Inc.Mar 2026$374.13M +27.1%-5.3%88.5%
PRTCPureTech Health plcDec 2025$305.68M -25.1%-17.7%57.2%
RCKTRocket Pharmaceuticals, Inc.Mar 2026$238.04M -42.2%-17.3%83.4%
NGNENeurogene Inc.Mar 2026$237.78M -18.5%+39.0%90.4%
QSIQuantum-Si incorporatedMar 2026$200.74M -18.7%-15.0%94.1%
BNTCBenitec Biopharma Inc.Mar 2026$183.33M +87.9%+223.2%98.0%
AUTLAutolus Therapeutics plcMar 2026$108.83M -70.7%-15.8%20.6%
NMRANeumora Therapeutics, Inc. Common StockMar 2026$70.68M -69.0%—45.9%
LCTXLineage Cell Therapeutics, Inc.Mar 2026$52.7M -32.1%-15.5%48.1%
ADCTADC Therapeutics S.A.Mar 2026-$216.38M +9.2%—74.2%
Peer median (excluding PRTC) $192.04M-18.6%-15.0%82.0%

Competitors are the stored peer set for PRTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents465.71M149.87M191.08M280.64M254.07M
Short-term Investments0200.23M136.06M86.67M24.83M
Net Receivables3.59M22.36M2.38M12.9M8.13M
Inventory28M0000
Other Current Assets(6.24M)2.12M13.37M1.64M11.42M
Total Current Assets501.81M386.19M347.2M386.26M305.02M
Property, Plant & Equipment (Net)43.94M37.24M19.36M15.13M11.5M
Goodwill00000
Intangible Assets987K831K906K601K601K
Long-term Investments398.46M60.81M325.63M200.17M217.43M
Tax Assets(398.46M)(60.81M)000
Other Non-current Assets399.27M278.39M879K476K166K
Total Non-current Assets444.2M316.45M346.77M216.38M229.69M
Total Assets946.01M702.65M693.97M602.64M534.71M
Account Payables11.35M26.5M14.64M5.52M3.07M
Short-term Debt5.5M7.5M3.7M4.11M4.92M
Tax Payables57K57K075K0
Deferred Revenue31.32M2.19M(29.47M)00
Other Current Liabilities152.01M29.4M29.64M27.18M31.7M
Total Current Liabilities226.14M96.89M51.37M41.39M46.31M
Long-term Debt14.26M10.24M000
Deferred Tax Liabilities89.77M19.65M52.46M00
Deferred Revenue (Non-current)00000
Other Non-current Liabilities2.66M4.13M113.66M138.64M171.64M
Total Non-current Liabilities135.72M58.17M184.37M153.31M182.73M
Total Liabilities361.86M155.06M235.74M194.7M229.03M
Common Stock5.44M5.46M5.46M4.86M4.86M
Retained Earnings199.87M149.52M83.82M32.49M61.28M
Accumulated OCI(39.61M)(14.39M)129.15M133.96M182K
Other Stockholders Equity98.9M124.12M00(3.35M)
Minority Interest(9.37M)5.37M(5.84M)(6.77M)(6.4M)
Total Equity584.15M547.59M458.23M407.93M305.68M
Total Debt52.75M46.87M25.34M22.36M19.76M
Net Debt(413.68M)(102.99M)(165.74M)(258.28M)(234.31M)

PureTech Health plc

NASDAQ:PRTC

Intrinsic Alpha fair value

Locked

Current Price

$17.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.